



**North American Association of Central Cancer Registries
Agreement for Administering the Central Cancer Registry
Inter-Registry Resident Data Exchange**

This Agreement establishes the terms and conditions for the exchange of resident cancer case information between participating member registries (“Trading Partners,” collectively) of the North American Association of Central Cancer Registries (“NAACCR”). This Agreement will be executed in counterparts by each Trading Partner, with each such signed Agreement deemed to be an original, and all such counterparts together shall constitute one and the same instrument. The executed counterparts of the Agreement shall be maintained by NAACCR, but NAACCR is not a party to the Agreement.

Each Trading Partner agrees to specify in detail any additional permissions and/or restrictions affecting the use, release and re-release of its information by other Trading Partners. These specifications will be included in the Addendum, hereby incorporated into this Agreement. Each Trading Partner agrees to update and keep current all information in the Addendum by informing NAACCR in writing of any changes to law statute, regulation or policy that impact this Agreement and expressly authorizes NAACCR to provide a copy of the Trading Partner’s executed counterpart (and any Addendum thereto), as may be revised or modified, to any other Trading Partner at any time.

Each Trading Partner may rescind or modify its participation in this Agreement by sending a written notice of rescission or a copy of revisions to NAACCR. Each Trading Partner acknowledges that it is its responsibility to provide written notification to NAACCR of any rescission or modification of its participation in this Agreement, including any revision of the Trading Partner’s Addendum or this Agreement.

By signing this Agreement, the central cancer registry listed below agrees to become a Trading Partner in the exchange of cancer incidence data, acting as the Sending Registry and/or the Receiving Registry with regard to resident cancer data for all other Trading Partners and hereby agrees that:

1. The Sending Registry will provide all cancer registry records and information concerning diagnosis and treatment of cancer occurring in non-residents and contained in the Sending Registry to the Receiving Registry where the reported cancer cases reside, except information specifically exempt from release by the Sending Registry in accordance with the restrictions in the Addendum.
2. Information will be provided electronically, whenever practical. The latest data core edits will be run on the data by the Sending Registry, and the data shall be formatted to follow the most current NAACCR data exchange record layout, shall contain sufficient information to be used for statistical and administrative purposes, and shall be transmitted through a mutually agreed-upon secure method that ensures against inappropriate access to the information.
3. All transmittals of cancer registry records are to be made following a timetable mutually agreed upon by Trading Partners. To ensure optimum utilization of the records, Trading Partners shall make every reasonable effort to forward all cancer case reports within eighteen (18) months of the end of the diagnosis year.
4. The information exchanged under this Agreement may only be used by the Receiving Registry for purposes authorized in Paragraph 7 of this Agreement or any other purposes authorized in writing by the Sending Registry. The Receiving Registry agrees to use records containing identifiable information exchanged under this Agreement in full compliance with the terms and conditions of this Agreement and any specific conditions required by the Sending Registry in the Addendum. Identifiable information exchanged under this Agreement may not be re-released by the Receiving Registry without written permission of the Sending Registry.

For the purpose of this Agreement, identifiable information shall be defined as in the HIPAA Privacy Rule (45 CFR 164.514).


5. Any and all data that may lead to the identification of any patient is strictly privileged and confidential, and the Receiving Registry agrees to keep all such data strictly confidential.
6. A Receiving Registry shall maintain the confidentiality of the exchanged patient identifying data and has legal protections in place under state and/or federal law to be able to protect the data from release in

13. This Agreement shall remain in effect as to any Trading Partner from the date of its execution until a duly authorized representative of that Trading Partner notifies the other Trading Partners of a change or termination of this Agreement through written notification to NAACCR.

14. All notices required or desired to be made to this Agreement by any Trading Partner shall be sent to NAACCR as well as to any Receiving Registry of the Trading Partner.


Trading Partner:

Central Cancer Registry: Louisiana Tumor Registry
Xiao-Cheng Wu, MD, MPH, CTR, Director
2020 Gravier St, 3rd Floor
New Orleans, LA 70112



Signature Date 9/11/2014

Agency: Louisiana State University Health Sciences Center – New Orleans
Joseph M. Moerschbaeche, III, PhD
Vice Chancellor for Academic Affairs
433 Bolivar Street
New Orleans, LA 70112



Signature Date 9/15/14

CONTACT PERSON:

Name: Patricia Andrews
Title: Registry liaison
Address: 2020 Gravier St, 3rd Floor, New Orleans, LA 70112
Email: pandre@lsuhsc.edu Phone: 504/568-5795 Fax: 504/568-5800

CONTACT PERSON FOR ELECTRONIC EXCHANGE:

Name: Meichin Hsieh
Title: Registry data manager
Address: 2020 Gravier St, 3rd Floor, New Orleans, LA 70112
Email: mhsieh@lsuhsc.edu Phone: 504/568-5850 Fax: 504/568-5800

MAIL RECORDS TO:

Name: Meichin Hsieh
Title: Registry data manager
Address: 2020 Gravier St, 3rd Floor, New Orleans, LA 70112
Email: mhsieh@lsuhsc.edu Phone: 504/568-5850 Fax: 504/568-5800

Addendum to Trading Partner Agreement of Louisiana Tumor Registry

Additional permissions and restrictions on the use of cancer registry information from this Trading Partner.

1: Cancer case information supplied by the Louisiana Tumor Registry (LTR) can be used for any registry related purpose as outlined above, but release of identifiable or potentially re-identifiable LTR data is not permitted without the prior written approval of the LTR. This includes release for research as listed in item 7c of the Standard Agreement. 2: The Receiving Registry will notify the Louisiana Tumor Registry (LTR) if, in the conduct of approved research or other activities involving the LTR's data, there is a breach or misuse of a cancer patient's identifying information or potentially identifying information. Should a breach or misuse take place, the Receiving Registry must notify the LTR in writing within forty-eight (48) hours of the release of the data, and shall take all feasible measures to mitigate loss or damages related to such breach or misuse, including, but not limited to, bearing sole responsibility for reasonable costs, including attorneys' fees, related to mitigating the breach or misuse to the extent authorized by Louisiana state law.